Wie hoch ist der Preis für Marinus Pharmaceuticals, Inc. (MRNS)

Preis für Marinus Pharmaceuticals, Inc. (MRNS) ist $0.55

Wie hoch ist die Marktkapitalisierung für Marinus Pharmaceuticals, Inc. (MRNS)

Marktkapitalisierung für Marinus Pharmaceuticals, Inc. (MRNS) ist $28.90M

Marinus Pharmaceuticals, Inc. (MRNS) KBV

Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.

Jahr	P/B-Verhältnis	ändert
2026 (TTM)	1.76	-79.78%
2023	8.72	2,502.21%
2022	0.34	-83.55%
2021	2.04	236.14%
2020	0.61	80.74%
2019	0.34	-21.91%
2018	0.43	-48.12%
2017	0.83	261.21%
2016	0.23	-62.26%
2015	0.61	53.71%
2014	0.40	-76.83%
2013	1.71	-55.78%
2012	3.86	0.00%

Jahr

P/B-Verhältnis

ändert

2026 (TTM)

1.76

-79.78%

2023

8.72

2,502.21%

2022

0.34

-83.55%

2021

2.04

236.14%

2020

0.61

80.74%

2019

0.34

-21.91%

2018

0.43

-48.12%

2017

0.83

261.21%

2016

0.23

-62.26%

2015

0.61

53.71%

2014

0.40

-76.83%

2013

1.71

-55.78%

2012

3.86

0.00%

Unternehmen	P/B-Verhältnis	P/B-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	259.68%	US
Moderna, Inc. MRNA.US	3.7087	110.34%	US
Argenx SE ARGX.US	6.2413	253.98%	NL
CSL Limited CSL.AX	2.5054	42.09%	AU
Lonza Group AG LONN.SW	-	-	CH

Unternehmen

P/B-Verhältnis

P/B-Verhältnis-Differenz

Land